Prakash Gudsoorkar,Meghan E Sise,Kenar D Jhaveri
Prakash Gudsoorkar
Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease-From Bench to Bedside [0.03%]
糖尿病肾病的新型抗炎和抗纤维化药物——从实验室到临床
Susanne B Nicholas
Susanne B Nicholas
Chronic low-grade inflammation, now coined by the new paradigm as "metaflammation" or "metainflammation", has been linked to chronic kidney disease and its progression. In diabetes, altered metabolism denotes factors associated with the met...
Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents [0.03%]
盐皮质激素受体拮抗剂-证据与新药试验肾脏保护作用
Omar Al Dhaybi,George L Bakris
Omar Al Dhaybi
The area of aldosterone blockade has exploded in the last decade with the development of four new compounds of a different class referred to as nonsteroidal mineralocorticoid receptor antagonists (MRAs). Their chemistry and clinical charatc...
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation [0.03%]
固体器官移植患者的新型降糖疗法
Pitchaphon Nissaisorakarn,Martha Pavlakis,Amtul Aala
Pitchaphon Nissaisorakarn
Post-transplant diabetes mellitus is a frequent consequence of or a pre-existing comorbidity in solid organ transplantation (SOT) that is associated with greater morbidity and mortality. Novel glucose-lowering agents that have been shown to...
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes [0.03%]
胰高糖素样肽1受体激动剂治疗对2型糖尿病患者肾脏结局的影响
Ofri Mosenzon,Meir Schechter,Gil Leibowitz
Ofri Mosenzon
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV di...
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists [0.03%]
GLP-1受体激动剂心血管及肾脏保护机制专家共识
Kalie L Tommerdahl,Kristen J Nadeau,Petter Bjornstad
Kalie L Tommerdahl
The worldwide prevalence of type 2 diabetes (T2D) is steadily increasing, and it remains a challenging public health problem for populations in both developing and developed countries around the world. Despite the recent advances in novel a...
Domenico Tricò,Anna Solini
Domenico Tricò
In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with thei...
Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned [0.03%]
糖尿病肾病新疗法实施障碍及经验教训
Joshua J Neumiller,Radica Z Alicic,Katherine R Tuttle
Joshua J Neumiller
As a result of the growing number of patients with type 2 diabetes mellitus, the prevalence of diabetic kidney disease (DKD) has proven to be one of the fastest growing health care challenges globally. Early detection and initiation of appr...
Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus [0.03%]
用于1型糖尿病成人和儿童患者的钠-葡萄糖协同转运蛋白抑制作用
Rebecca J Vitale,Lori M Laffel
Rebecca J Vitale
Adjunctive therapies to insulin for treatment of type 1 diabetes mellitus (T1D) have gained popularity in efforts to achieve glycemic targets, and sodium-glucose transporter (SGLT) inhibitors are an appealing option due to associated weight...
Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes [0.03%]
钠-葡萄糖共转运蛋白2抑制剂在糖尿病患者和非糖尿病患者中的肾脏及心血管保护作用的理论依据与机制
Carol Pollock,Brendon L Neuen
Carol Pollock
Large-scale randomized trials have demonstrated the remarkable capacity of sodium-glucose cotransporter 2 inhibitors to reduce the risk of cardiovascular outcomes and kidney disease progression, irrespective of the presence or absence of ty...